High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events
Article first published online: 6 OCT 2010
© 2010 International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis
Volume 8, Issue 10, pages 2140–2148, October 2010
How to Cite
BREET, N. J., VAN WERKUM, J. W., BOUMAN, H. J., KELDER, J. C., TEN BERG, J. M. and HACKENG, C. M. (2010), High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. Journal of Thrombosis and Haemostasis, 8: 2140–2148. doi: 10.1111/j.1538-7836.2010.04017.x
- Issue published online: 6 OCT 2010
- Article first published online: 6 OCT 2010
- Accepted manuscript online: 12 AUG 2010 12:00AM EST
- Received 5 May 2010, accepted 23 July 2010
Fig. S1. Receiver operating characteristic curve.
Table S1. Baseline characteristics of the subpopulations according to the available platelet function measurements.
Table S2. Baseline characteristics of the study population according to the magnitude of platelet reactivity.
Table S3. Clinical Outcome using cut-off values derived from the literature.
|JTH_4017_sm_suppmat.doc||29K||Supporting info item|
|JTH_4017_sm_Slide1.TIF||57K||Supporting info item|
|JTH_4017_sm_Slide2.TIF||59K||Supporting info item|
|JTH_4017_sm_Slide3.TIF||108K||Supporting info item|
|JTH_4017_sm_Slide4.TIF||57K||Supporting info item|
|JTH_4017_sm_Table-1Baseline-characteristics.doc||64K||Supporting info item|
|JTH_4017_sm_Table2-Baseline-NPRHPR.doc||171K||Supporting info item|
|JTH_4017_sm_Table3-ClinicalOutcomeliterature.doc||50K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.